Pulmatrix (PULM) Stock Price Up 6.5%

Shares of Pulmatrix Inc (NASDAQ:PULM) rose 6.5% during trading on Tuesday . The company traded as high as $1.15 and last traded at $1.15. Approximately 2,096,999 shares traded hands during mid-day trading, an increase of 33% from the average daily volume of 1,574,570 shares. The stock had previously closed at $1.08.

PULM has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating on shares of Pulmatrix in a research note on Tuesday, April 16th. Zacks Investment Research upgraded Pulmatrix from a “hold” rating to a “buy” rating in a research note on Saturday, April 20th.

The firm has a market capitalization of $8.67 million, a price-to-earnings ratio of -0.23 and a beta of 1.58.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings results on Tuesday, February 19th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.92. Equities research analysts predict that Pulmatrix Inc will post -1.97 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Pulmatrix (PULM) Stock Price Up 6.5%” was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://dakotafinancialnews.com/2019/05/15/pulmatrix-pulm-stock-price-up-6-5.html.

About Pulmatrix (NASDAQ:PULM)

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

Recommended Story: How is a Moving Average Calculated?

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.